LAB Publishers - Scientific Publisher

Case Report

ORAL MUCOSA PIGMENTATION RELATED TO IMATINIB MESYLATE: A CASE REPORT

A. Romano1 ORCID

1 Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", Naples, Italy

Correspondence to:

Antonio Romano, DDS
Multidisciplinary Department of Medical-Surgical and Dental Specialties,
University of Campania "Luigi Vanvitelli",
Naples, Italy

Annals of Stomatology 2022 May-August; 2(2): 68-70
DOI https://doi.org/10.69129/stomatol/2022v2iss2_5


Received: 14 June 2022 Accepted: 12 July 2022

Copyright © by LAB srl 2022 ISSN 2975-1276
This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties. Disclosure: All authors report no conflicts of interest relevant to this article.

Download Download PDF

Abstract

Imatinib Mesylate (IM), a tyrosine kinase inhibitor, is a first-line medication for treating chronic myeloid leukemia and gastrointestinal stromal tumors. Clinical studies revealed excellent hematological responses without significant side effects. Dermatologic side effects are ordinary, with rash and superficial edema the most recurring. Moreover, IM treatment is often associated with hypopigmentation. Intraoral side effects are very infrequent. However, IM may lead to mucosal pigmentation. This paper reports a patient with chronic myeloid leukemia treated with IM for seven years, referred with diffuse solitary bluish-brown pigmentations in the hard palate.